Patents by Inventor Hyun Sook Hwang

Hyun Sook Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
    Patent number: 10196396
    Abstract: The present disclosure provides compounds useful in the amelioration, prevention or treatment of A3 adenosine receptor mediated diseases, such as glaucoma and glaucoma-related ocular disorders, having the structure of Formula I as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for ameliorating, preventing or treating A3 adenosine receptor mediated diseases using the compound.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 5, 2019
    Assignee: HANDOK INC.
    Inventors: Jin-Hwa Lee, Seung-Yong Kim, Do-Ran Kim, Koo-Hyeon Ahn, Gwi-Bin Lee, Doo-Seop Kim, Hyun-Sook Hwang
  • COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF
    Publication number: 20170204101
    Abstract: The present disclosure provides compounds useful in the amelioration, prevention or treatment of A3 adenosine receptor mediated diseases, such as glaucoma and glaucoma-related ocular disorders, having the structure of Formula I as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for ameliorating, preventing or treating A3 adenosine receptor mediated diseases using the compound.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 20, 2017
    Applicant: HANDOK INC.
    Inventors: Jin-Hwa Lee, Seung-Yong Kim, Do-Ran Kim, Koo-Hyeon Ahn, Gwi-Bin Lee, Doo-Seop Kim, Hyun-Sook Hwang
  • Arylsulfonylimidazolone derivatives as an antitumor agent
    Patent number: 5932742
    Abstract: The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which - -, R.sub.1, and R.sub.2 are as defined in the specification.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: August 3, 1999
    Assignee: Dong Wha Pharm. Ind. Co., Ltd.
    Inventors: Sung June Yoon, Yong Ho Chung, Moon Sun Lee, Dong Rack Choi, Jung A Lee, Hee Soon Lee, Hae Ran Yun, Dug Keun Lee, Eun Yi Moon, Hyun Sook Hwang, Chung Ha Choi, Sang Hun Jung
  • Arylsulfonylimidazolone derivatives as an antitumor agent
    Patent number: 5929103
    Abstract: The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which ----, R.sub.1, and R.sub.2 are as defined in the specification.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: July 27, 1999
    Assignee: Dong Wha Pharm. Ind. Co., Ltd.
    Inventors: Sung June Yoon, Yong Ho Chung, Moon Sun Lee, Dong Rack Choi, Jung A Lee, Hee Soon Lee, Hae Ran Yun, Dug Keun Lee, Eun Yi Moon, Hyun Sook Hwang, Chung Ha Choi, Sang Hun Jung